Sol Langermann, Ph.D. | Chief Scientific Officer
|Most recently, Dr. Langermann served as Senior Vice President and Chief Scientific Officer (CSO) of Amplimmune (now MedImmune/AstraZeneca). Amplimmune was focused on developing novel immunotherapeutics in the areas of cancer, autoimmunity, infectious diseases and transplantation. Dr. Langermann played a critical role in building Amplimmune to achieve its goals of rapid translation of lead candidates from discovery, validation, scaled up production and characterization into proof-of-concept clinical trials. This led to multiple INDs and to successful partnering activities with GlaxoSmithKline, Daiichi Sankyo and the acquisition by AstraZeneca. Prior to joining Amplimmune, Dr. Langermann held several positions at MedImmune, including Senior Director of Cell Biology, Director of Immunology and Molecular Genetics and Research Scientist in Immunology. While at MedImmune he also held a position as an Adjunct Professor at University of Maryland School of Medicine in the Department of Medical and Research Technology. Subsequent to his tenure at MedImmune, Dr. Langermann was at PharmAthene (now Altimmune) where he headed up Research and Development efforts, and served as CSO at both their Annapolis, Maryland and Montreal, Canada sites. Dr. Langermann received his Ph.D. from Tufts University and completed his postdoctoral fellowship as well as a Master’s degree at Harvard University.||• Michael Richman
President & CEO
• Steven P. Cobourn, CPA
• Kevin N. Heller, M.D.
• James B. Bingham, Ph.D.
• Sol Langermann, Ph.D.
• Linda Liu, Ph.D.
Senior Vice President, Research
• Timothy Mayer, Ph.D.
Senior Vice President, Corporate Development
• Sebastien Maloveste, Ph.D.
Vice President, Business Development
• Dallas Flies, Ph.D.
Vice President, Discovery Research